CSPC Innovation Pharmaceutical (300765) Q3 2025 earnings summary

Executive summary

• Revenue for the first nine months of 2025 reached ¥1,593 million, up 7.71% year-over-year.

• Net loss attributable to shareholders was ¥24.05 million, a significant decline from a profit in the prior year.

• The company increased its stake in subsidiary Jushi Biopharma from 51% to 80% for ¥1.1 billion, aiming to strengthen its position in innovative biopharmaceuticals.

Financial highlights

• Q3 revenue was ¥543.46 million, up 7.18% compared to the same quarter last year.

• Net loss for Q3 was ¥21.30 million, a sharp reversal from a profit in the prior year.

• Operating cash flow for the first nine months was negative ¥175.12 million, an improvement of 81.67% year-over-year.

• Total assets at quarter-end were ¥6,210.88 million, up 3.13% from year-end 2024.

• Shareholders’ equity decreased by 1.15% to ¥3,687.76 million.

Outlook and guidance

• The company is deepening its strategic focus on innovative biopharmaceuticals, expecting the acquisition of additional Jushi Biopharma equity to enhance long-term value.